Scientists have created a mouse model of muscular dystrophy in which degenerating muscle tissue gives off visible light. The observed luminescence occurs only in damaged muscle tissue and in direct proportion to cumulative damage sustained in that tissue.
Ironwood Pharmaceuticals Inc. reported disappointing first-quarter results, including a bigger loss and less revenue than analysts expected. Ironwood and its partner, Forest Laboratories Inc., are selling the bowel drug Linzess, which reached the market in December, driving up Ironwood's marketing costs.
High Efficiency Screening (HES) has been shown to identify significant lead compounds with only a tiny fraction of the expense and effort of traditional high-throughput drug screening.
Preclinical Oncology Services Ltd. has launched PRECOS Unique Models of Acquired resistance (PUMA). Derived from cell lines and proprietary PDX models, PUMA models provide a unique bespoke collection of clinically relevant and validated models of resistance.
The CaptairBio PCR Workstations uses a UV lamp, which allows the working environment to be decontaminated in order to prevent contamination of samples. Air from the laboratory passes through a HEPA H14 filter, which is over 99.995% effective at trapping particles 0.1 microns and higher.
Janssen announced results from two Phase 3 studies demonstrating that simeprevir led to sustained virologic response in 80% of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease when administered once daily with pegylated interferon and ribavirin.
Sucampo Pharmaceuticals Inc. and Takeda Pharmaceuticals said that they received U.S. regulatory to market their constipation treatment Amitiza for a new use. The Food and Drug Administration approved the pill for constipation caused by opioid pain medications used by patients with non-cancer chronic pain.
Forest Laboratories Inc.'s fiscal fourth-quarter earnings plunged 76%, as the drug developer's revenue continued to take a hit from a key patent loss. The New York company said that it earned almost $150 million less this quarter than a year earlier.
An investigational treatment for an inherited form of Lou Gehrig’s disease has passed an early phase clinical trial for safety. The researchers have shown that the therapy produced no serious side effects in patients with the disease, also known as amyotrophic lateral sclerosis.
For children who have had HIV-1 infection since birth, the combination drug therapies now used to treat HIV appear to protect against the heart damage seen before combination therapies were available, according to researchers in a National Institutes of Health network study.
An analyst has upgraded his outlook for AbbVie Inc., expecting greater sales of the company's blockbuster anti-inflammatory drug Humira and several experimental products. He thinks AbbVie shares will trade higher as the company continues to report progress for its drugs in clinical development.
Medicyte has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next generation, cell-based upcyte cell products to the biopharma and academic research markets.
Integrated DNA Technologies launches an enhanced version of the open access PrimerQuest online tool, for efficient PCR primer and probe design. Selection parameters have been optimized with built-in presets for a diverse range of applications, to produce the very best primers and probes.
The NEXTflex 16S V4 Amplicon-Seq Kit has been developed to simplify bacterial metagenomics studies using Illumina HiSeq and MiSeq platforms. This kit allows users to go from sample to sequence in two hours, making it the fastest library prep kit available.
Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumors in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.